<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Cambridge Epigenetix 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=32337></link><description><![CDATA[Cambridge Epigenetix 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Thu, 30 Apr 2026 14:58:35 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2019/01/3698601005_20190109090728_1813939832.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[Cambridge Epigenetix announces programme for routine screening and detection of colorectal cancer and other common tumours]]></title><link>https://www.newswire.co.kr/newsRead.php?no=881757</link><description><![CDATA[CAMBRIDGE, England--(Business Wire/Korea Newswire)--Cambridge Epigenetix Ltd, a pioneer in the development and application of epigenetic technologies, today announces its discovery and development programme for a test to detect colorectal and other cancers. This follows completion of a c. $30 million funding round, as well as the acquisition of exclusive patent rights for its epigenetic sequencin...]]></description><pubDate>Wed, 09 Jan 2019 09:15:00 +0900</pubDate></item></channel></rss>